News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results PR Newswire LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144 treatment Obser...
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022 PR Newswire SALT LAKE CITY , May 9, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendo...
LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS PR Newswire Industry veterans Jill M. Jene , Ph.D. and Spyros Papapetropoulos M.D. Ph.D. appointed to Board SALT LAKE CITY , April 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a b...